Intravenous golimumab in rheumatoid arthritis
Authors:
- Edward C KeystoneEKEdward C Keystone
- 15 May 2014
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 10 (7) , 823-830
Abstract
Intravenous golimumab in a dosage of 2 mg/kg, initially given every 4 weeks but then every 8 weeks, in addition to methotrexate, is effective in the treatment of patients with rheumatoid arthritis. This weight-based infusion is administered over thirty minutes with an acceptable safety profile. Since it is a relatively new formulation, more time will be required to assess its specific role in the rheumatologists' armamentarium and to appreciate more fully its long-term safety.Keywords
This publication has 15 references indexed in Scilit:
- Golimumab in psoriatic arthritis: One‐year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo‐controlled trialArthritis & Rheumatism, 2012
- Golimumab Pharmacokinetics After Repeated Subcutaneous and Intravenous Administrations in Patients with Rheumatoid Arthritis and the Effect of Concomitant Methotrexate: An Open-Label, Randomized StudyClinical Therapeutics, 2012
- The effects of golimumab on radiographic progression in rheumatoid arthritis: Results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapyArthritis & Rheumatism, 2011
- Subcutaneous Bioavailability of Golimumab at 3 Different Injection Sites in Healthy SubjectsThe Journal of Clinical Pharmacology, 2010
- Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis: Twenty‐four–week results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study of golimumab before methotrexate as first‐line therapy for early‐onset rheumatoid arthritisArthritis & Rheumatism, 2009
- Golimumab: A novel human anti-TNF-α monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritisCore Evidence, 2009
- Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trialThe Lancet, 2009
- Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD StudyAnnals of the Rheumatic Diseases, 2009
- Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double‐blind, placebo‐controlled, dose‐ranging studyArthritis & Rheumatism, 2008
- Pharmacokinetics and Safety of Golimumab, a Fully Human Anti‐TNF‐α Monoclonal Antibody, in Subjects With Rheumatoid ArthritisThe Journal of Clinical Pharmacology, 2007